logo
logo
PRAX stock ticker logo

Praxis Precision Medicines, Inc.

NASDAQ•PRAX
執行長: Mr. Marcio Silva De'Souza M.B.A.
板塊: Healthcare
行業: Biotechnology
上市日期: 2020-10-16
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
聯絡資訊
99 High Street, 30th Floor, Boston, MA, 02110, United States
617-300-8460
praxismedicines.com
市值
$5.64B
本益比 (TTM)
-23.6
24.5
股息率
--
52周最高
$366.52
52周最低
$37.19
52周範圍
70%
排名58Top 85.6%
2.3
F-Score
改良版 Piotroski 分析
基於 7 年期基本面
疲弱 • 2.3 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2019-2025

深度研究

財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表
過去12個月
無資料